Luis Paz‐Ares

93.4k citations
690 papers · 23.0k indexed · 15 hit papers · h-index 73
Topics
Lung Cancer Treatments and Mutations (375 papers)Lung Cancer Research Studies (235 papers)Cancer Immunotherapy and Biomarkers (167 papers)

In The Last Decade

Luis Paz‐Ares

655 papers receiving 22.5k citations

Hit Papers

Lung cancer: current therapies and new targeted treatments20112026201620212016201620182011201250010001.5k2.0k

Peers

Luis Paz‐Ares
Comparison fields: 5 of 156
  • Oncology 13.2k
  • Pulmonary and Respiratory Medicine 11.4k
  • Molecular Biology 7.6k
  • Cancer Research 4.2k
  • Surgery 2.3k
Replace Suresh S. Ramalingam with:
Suresh S. Ramalingam United States
Kenneth J. O’Byrne Australia
Lesley Seymour Canada
Giampaolo Tortora Italy
Byoung Chul Cho South Korea
Wilko Weichert Germany
Mark A. Socinski United States
David R. Gandara United States
Keunchil Park South Korea
Benjamin Solomon Australia
Luis Paz‐Ares relative to Suresh S. Ramalingam United States Suresh S. Ramalingam's profile →
Citations per field
00.5×1.6×
Suresh S. Ramalingam · 1×
Citations per year

Countries citing papers authored by Luis Paz‐Ares

Since Specialization
Citations

This map shows the geographic impact of Luis Paz‐Ares's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Paz‐Ares with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Paz‐Ares more than expected).

Fields of papers citing papers by Luis Paz‐Ares

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis Paz‐Ares. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Paz‐Ares. The network helps show where Luis Paz‐Ares may publish in the future.

Co-authorship network of co-authors of Luis Paz‐Ares

This figure shows the co-authorship network connecting the top 25 collaborators of Luis Paz‐Ares. A scholar is included among the top collaborators of Luis Paz‐Ares based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis Paz‐Ares. Luis Paz‐Ares is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 3
3 1
4 19
5 9
6 8
7 5
8 3
9 29
10 5
11 15
12 31
13
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy
1
14 17
15 232
16 257
17 200
18 15
19
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studybreakdown →
453
20 134

About Luis Paz‐Ares

Luis Paz‐Ares is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 690 papers that have together received 23.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (375 papers), Lung Cancer Research Studies (235 papers) and Cancer Immunotherapy and Biomarkers (167 papers). The work is most often cited by research in Oncology (13.2k citations), Pulmonary and Respiratory Medicine (11.4k citations) and Cancer Research (4.2k citations). Luis Paz‐Ares has collaborated with scholars based in Spain, United States and Germany. Frequent co-authors include Yi‐Long Wu, Fred R. Hirsch, Giorgio V. Scagliotti, Walter J. Curran, James L. Mulshine, Regina Kwon, Irene Ferrer, Rocio García‐Carbonero, Sonia Molina‐Pinelo and Amancio Carnero. Their work appears in journals such as The Lancet, Journal of Clinical Investigation and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026